Huadong Medicine: Hangzhou Subsidiary Secures Exclusive Commercialization Deal with Jiangsu Weikair for VC005

1 week ago / Read about 0 minute

Author：小编

Huadong Medicine's wholly-owned subsidiary, Huadong Medicine Hangzhou, has inked an agreement with Jiangsu Weikair, granting it exclusive rights to commercialize the oral formulation of VC005 in mainland China. VC005 tablets represent a novel, potent, and highly selective second-generation JAK1 inhibitor, tailored for the treatment of inflammatory and autoimmune diseases. Currently undergoing Phase III clinical trials for moderate to severe atopic dermatitis, this innovative drug holds promise for patients suffering from these conditions. Under the terms of the agreement, Huadong Medicine Hangzhou will make an initial payment of 50 million yuan, with potential registration milestone payments totaling up to 180 million yuan.

Previous page：Ministry of Foreign Affairs: China Denounces Polit...

Next page：Central Media Probes Alleged Backdoors in H20 Chip...

Return to List

Hot Reading

2 day ago

Trump's Anti-Science Agenda Is Massively Hampering His Plans for AI, Experts Warn

2 day ago

Is GPT-5 really worse than GPT-4o? Ars puts them to the test.

2 day ago

New Research Finds That ChatGPT Secretly Has a Deep Anti-Human Bias

2 day ago

Anthropic says some Claude models can now end ‘harmful or abusive’ conversations